Boothbay Fund Management’s Kezar Life Sciences KZR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-16,210
| Closed | -$120K | – | 2460 |
|
|
2026
Q1 | $120K | Hold |
16,210
| – | – | ﹤0.01% | 1857 |
|
|
2025
Q4 | $102K | Sell |
16,210
-4,690
| -22% | -$27.4K | ﹤0.01% | 1737 |
|
|
2025
Q3 | $81.5K | Hold |
20,900
| – | – | ﹤0.01% | 1749 |
|
|
2025
Q2 | $95.7K | Hold |
20,900
| – | – | ﹤0.01% | 1312 |
|
|
2025
Q1 | $102K | Hold |
20,900
| – | – | ﹤0.01% | 1227 |
|
|
2024
Q4 | $140K | Buy |
20,900
+1
| +0% | +$7 | ﹤0.01% | 1241 |
|
|
2024
Q3 | $162K | Buy |
20,899
+5,850
| +39% | +$35.3K | ﹤0.01% | 1413 |
|
|
2024
Q2 | $90.3K | Hold |
15,049
| – | – | ﹤0.01% | 1363 |
|
|
2024
Q1 | $136K | Buy |
15,049
+1,561
| +12% | +$14.2K | ﹤0.01% | 1387 |
|
|
2023
Q4 | $128K | Hold |
13,488
| – | – | ﹤0.01% | 1401 |
|
|
2023
Q3 | $161K | Buy |
13,488
+1,179
| +10% | +$20.9K | ﹤0.01% | 1475 |
|
|
2023
Q2 | $302K | Hold |
12,309
| – | – | 0.01% | 1294 |
|
|
2023
Q1 | $385K | Buy |
12,309
+4,332
| +54% | +$251K | 0.01% | 1378 |
|
|
2022
Q4 | $562K | Sell |
7,977
-387
| -5% | -$28.7K | 0.01% | 1129 |
|
|
2022
Q3 | $720K | Sell |
8,364
-7,810
| -48% | -$759K | 0.02% | 1048 |
|
|
2022
Q2 | $1.34M | Buy |
16,174
+4,869
| +43% | +$429K | 0.04% | 702 |
|
|
2022
Q1 | $1.88M | Hold |
11,305
| – | – | 0.04% | 603 |
|
|
2021
Q4 | $1.89M | Buy |
+11,305
| New | +$1.28M | 0.04% | 502 |
|
Boothbay Fund Management's KZR Position: Q2 2026 in Review
Boothbay Fund Management sold out of Kezar Life Sciences (KZR) in Q2 2026, closing a stake of 16,210 shares — an estimated $120K sold.
Boothbay Fund Management first reported a position in KZR in Q4 2021 and held it in 18 quarters. The position peaked at $1.89M in Q4 2021. 0 funds tracked by Wall St. Rank hold KZR as of Q2 2026.
- Boothbay Fund Management reported no remaining Kezar Life Sciences position as of Q2 2026 after selling out during the quarter.
- Boothbay Fund Management sold 16,210 Kezar Life Sciences shares in Q2 2026, an estimated $120K.
- Boothbay Fund Management first reported a position in Kezar Life Sciences in Q4 2021 and held it in 18 quarters.
- Boothbay Fund Management's Kezar Life Sciences position peaked at $1.89M in Q4 2021.
- 0 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2026.
Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.